Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

den Broeder Alfons A.; van den Bemt Bart J. F.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

【24h】

Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

机译：评论L'AMI等人以高血清Adalimalab浓度的患者为标题为“患者的过度曝光患者的过度稳定性：开放标签，非劣等，随机临床试验”

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2018年第10期|共1页
作者
den Broeder Alfons A.; van den Bemt Bart J. F.;
展开▼
作者单位

Sint Maartensklin Reumatol NL-6522 JV Nijmegen Netherlands;

Sint Maartensklin Pharm Nijmegen Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al [J] . LAmi Merel J., Krieckaert Charlotte L. M., Nurmohamed Michael T., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第10期

机译：回应：对L'Ami等人的评论，标题为患有类风湿性关节炎患者的患者过度抑制的患者浓度：Den Broeder等人的开放标签，非劣等，随机临床试验'
2. Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' [J] . den Broeder Alfons A., van den Bemt Bart J. F. Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第10期

机译：评论L'AMI等人以高血清Adalimalab浓度的患者为标题为“患者的过度曝光患者的过度稳定性：开放标签，非劣等，随机临床试验”
3. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial [J] . lAmi Merel J., Krieckaert Charlotte L. M., Nurmohamed Michael T., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第4期

机译：用高血清Adalimalab浓度的类风湿性关节炎患者的患者过度曝光的成功减少：开放标签，非劣质性，随机临床试验
4. Immunogenic HLA-DR-presented-peptides Identified from Clinical Samples of Synovial Tissue/Fluid and Peripheral Blood from Patients with Rheumatoid Arthritis or Lyme Arthritis [C] . Qi Wang, Elise E. Drouin, Chunxiang Yao, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：免疫原性HLA-DR呈递肽，从类风湿性关节炎或莱姆关节炎患者的滑膜组织/液体和外周血的临床样本中鉴定出来
5. Clinical studies of immunomodulatory activities of Yunzhi -Danshen in breast cancer and nasopharyngeal carcinoma patients, and Lingzhi-San Miao San in rheumatoid arthritis patients. [D] . Bao, Yixi. 2005

机译：云芝丹参对乳腺癌和鼻咽癌患者及类风湿关节炎灵芝三妙散的免疫调节活性的临床研究。
6. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label randomised controlled non-inferiority trial [O] . Noortje van Herwaarden, Aatke van der Maas, Michiel J M Minten, 2015

机译：与类风湿关节炎的常规治疗相比疾病活动指导的阿达木单抗或依那西普的剂量减少和停用：开放标签随机对照非劣效性试验
7. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial [O] . Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, 2021

机译：使用Adalimalab血清浓度选择随后的类风湿性关节炎患者的后续生物DMARD，未降低Adalimalab治疗（addora-switch）：用于全面盲目的随机性优势测试治疗试验的研究方案

Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

著录项

相似文献

相关主题

期刊订阅